Latest Rosiglitazone Stories
DALLAS (Reuters) - A diabetes drug sold by Takeda Pharmaceutical Co. and Eli Lilly and Co. significantly cut the rate of a second heart attack compared with a placebo in high-risk patients with type-2 diabetes, a study reported on Wednesday found. The data come from a secondary analysis of a failed trial of the drug Actos reported in September, which had a more ambitious main goal of preventing a wider range of cardiovascular incidents, including death, stroke, and heart attack in...
CHICAGO (Reuters) - The experimental diabetes drug Pargluva, made by Merck and Co. Inc. and Bristol-Myers Squibb, may carry risks for heart attacks and cancer and should be studied further, researchers said on Thursday. Of the diabetic patients who took the drug in company-funded trials, 1.47 percent suffered a heart attack, a stroke or died, more than double the rate among those taking a placebo or an already approved drug, Cleveland Clinic researcher Steven Nissen wrote in the...
LONDON (Reuters) - Giving diabetes patients Takeda Pharmaceutical Co. Ltd.'s drug Actos not only lowers their blood sugar levels but also protects them from heart attacks, researchers said on Monday. A 5,200-patient clinical study found that Actos, when added to standard therapy, reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk people with type II diabetes, compared to conventional therapy alone. Actos, which is co-promoted by Eli Lilly and Co.,...
SILVER SPRING, Maryland (Reuters) - An experimental diabetes pill to lower blood sugar and certain blood fats won support on Friday from U.S. advisers despite concerns that it might contribute to heart failure. The medicine, Pargluva, is being developed by Bristol-Myers Squibb Co. and Merck & Co. Inc.. A panel of outside advisers to the Food and Drug Administration (FDA) voted 8-1 to urge approval for Pargluva as a stand-alone treatment for the most common form of diabetes, Type 2,...
SILVER SPRING, Md. (Reuters) - An experimental diabetes pill to lower blood sugar and certain blood fats won support on Friday from U.S. advisers despite concerns that it might contribute to heart failure. The medicine, Pargluva, is being developed by Bristol-Myers Squibb Co. and Merck & Co. Inc.. A panel of outside advisers to the Food and Drug Administration (FDA) voted 8-1 to urge approval for Pargluva as a stand-alone treatment for the most common form of diabetes, Type 2, which...
By Megan Rauscher NEW YORK (Reuters Health) - Diabetic patients with abnormally high liver enzymes are not at increased risk for developing liver toxicity from treatment with Avandia (rosiglitazone), results of a study indicate. Avandia "can be safely used" in these patients, Dr. Naga Chalasani who led the study told Reuters Health. Avandia belongs to a class of drugs called thiazolidinediones, which help lower blood sugar, or glucose, in people with type 2 diabetes. Although Avandia and a...
(Corrects name in headline from Rosiglitazone to Avandia)A corrected version follows By Megan Rauscher NEW YORK (Reuters Health) - Diabetic patients with abnormally high liver enzymes are not at increased risk for developing liver toxicity from treatment with Avandia (rosiglitazone), results of a study indicate. Avandia "can be safely used" in these patients, Dr. Naga Chalasani who led the study told Reuters Health. Avandia belongs to a class of drugs called thiazolidinediones, which help...
By Megan Rauscher NEW YORK (Reuters Health) - Diabetic patients with elevated baseline liver enzymes are not at increased risk of hepatotoxicity from treatment with the thiazolidinedione rosiglitazone, results of a study suggest. "Rosiglitazone can be safely used in diabetic patients with fatty liver disease," study leader Dr. Naga Chalasani told Reuters Health. Although the second-generation thiazolidinediones -- rosiglitazone and pioglitazone -- are "generally very safe from a hepatic...
